Synergy between Toxoplasma gondii type I Δ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
(2021)
Journal Article
Zhu, Y. C., Elsheikha, H. M., Wang, J. H., Fang, S., He, J. J., Zhu, X. Q., & Chen, J. (2021). Synergy between Toxoplasma gondii type I Δ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. Journal for ImmunoTherapy of Cancer, 9(11), Article e002970. https://doi.org/10.1136/jitc-2021-002970
Background: In this study, we hypothesize that the ability of the protozoan Toxoplasma gondii to modulate immune response within the tumor might improve the therapeutic effect of immune checkpoint blockade. We examined the synergetic therapeutic acti... Read More about Synergy between Toxoplasma gondii type I Δ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors.